Showing 1 - 8 results of 8 for search 'Jason P Mendoza', query time: 0.04s Refine Results
  1. 1
    CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.

    CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease. by Andrew F Tyler, Jason P Mendoza, Mihail Firan, Nitin J Karandikar

    Published 2013-01-01
    Get full text
    Article
  2. 2
    A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod

    A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod by Amber Salter, Samantha Lancia, Gary Cutter, Ruth Ann Marrie, Jason P. Mendoza, James B. Lewin, Robert J. Fox

    Published 2021-06-01
    Get full text
    Article
  3. 3
    Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis

    Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis by Brittney Lager, Jacob Liseno, Ivan Božin, Sarah M. England, Sai L. Shankar, Jason P. Mendoza, James B. Lewin

    Published 2022-11-01
    Get full text
    Article
  4. 4
    Response to Letter to the Editor Regarding “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”

    Response to Letter to the Editor Regarding “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis” by Brittney Lager, Jacob Liseno, Ivan Božin, Sarah M. England, Sai L. Shankar, Jason P. Mendoza, James B. Lewin

    Published 2023-09-01
    Get full text
    Article
  5. 5
    COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy

    COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy by Aliya Jaber, Meera Patel, Andrew Sylvester, Mary Yarussi, J. Tamar Kalina, Jason P. Mendoza, Robin L. Avila, Matthew A. Tremblay

    Published 2023-02-01
    Get full text
    Article
  6. 6
    Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM

    Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM by Angel Chinea, Lilyana Amezcua, Wendy Vargas, Annette Okai, Mitzi J. Williams, Ray Su, Becky Parks, Jason P. Mendoza, James B. Lewin, Cynthia C. Jones

    Published 2020-05-01
    Get full text
    Article
  7. 7
    Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM

    Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM by Mitzi J. Williams, Lilyana Amezcua, Annette Okai, Darin T. Okuda, Stanley Cohan, Ray Su, Becky Parks, Jason P. Mendoza, James B. Lewin, Cynthia C. Jones

    Published 2020-05-01
    Get full text
    Article
  8. 8
    Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies

    Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies by Lilyana Amezcua, Yang Mao-Draayer, Wendy S. Vargas, Rebecca Farber, Sara Schaefer, Filipe Branco, Sarah M. England, Nicholas Belviso, James B. Lewin, Jason P. Mendoza, Sai L. Shankar, the ENDORSE Study Investigators

    Published 2023-04-01
    Get full text
    Article

Search Tools: